Related Experiment Video

Updated: Feb 5, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.3K

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

John D Strickley1, Aaron C Spalding2, M Tye Haeberle3

  • 11University of Louisville School of Medicine, 323 E Chestnut St, Louisville, KY 40202 USA.

Experimental Hematology & Oncology
|September 6, 2018
PubMed
Abstract

Insights

A patient with advanced skin cancer (cutaneous squamous cell carcinoma) responded well to lapatinib, a drug targeting an ERBB3 mutation. This highlights the potential of ERBB2-targeted therapies for similar cancers with specific mutations.

Area of Science:

  • Oncology
  • Genomics
  • Dermatology

Background:

  • Lapatinib, a tyrosine kinase inhibitor, targets the HER2 receptor, commonly used for metastatic breast cancer.
  • ERBB2 (HER2) and ERBB3 (HER3) are receptor tyrosine kinases; their dimerization activates cell proliferation pathways.
  • Next-generation sequencing (NGS) enables detection of ERBB receptor mutations for personalized cancer therapy.

Observation:

  • A patient with metastatic cutaneous squamous cell carcinoma (CSCC) received treatment after failing surgery, radiation, and anti-PD1 therapy.
  • NGS identified an ERBB3 mutation in the patient's tumor.
  • The patient was treated with lapatinib, a drug targeting ERBB3 mutations.

Findings:

  • The patient exhibited a dramatic clinical response to lapatinib.
  • Tumor regression was observed in the skin, soft tissue, bone, and nerves.
  • This indicates a significant therapeutic effect of ERBB3-targeted therapy in this case.

Implications:

  • Cutaneous squamous cell carcinoma is a common skin cancer with limited treatment options for advanced stages.
  • Targeting ERBB2/3 pathways with therapies like lapatinib may offer a new treatment strategy for CSCC patients with relevant mutations.
  • Further investigation into ERBB2-targeted therapies is warranted for patients with ERBB2/3 pathway mutations.
Keywords:
ERBB3LapatinibMetastatic cutaneous squamous cell carcinomaNext generation sequencing

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

847
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

Related Concept Videos

Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
3.7K
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
3.1K
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.3K
Diversity in Cell Signaling Responses01:22

Diversity in Cell Signaling Responses

The physiological function of a cell and cellular communication are outcomes of a range of extrinsic signals, intracellular signaling pathways, and cellular responses. No two cell types express the same repertoire of signaling components. Receptors are highly selective for their cognate ligands, but once activated, they can alter multiple cellular processes such as DNA transcription, protein synthesis, and metabolic activity. 
Graded and Abrupt Responses
Some signaling systems generate...
8.0K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
84.1K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.9K